Moderna Inc Revenue Growth Rates (MRNA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Moderna Inc   (NASDAQ: MRNA)
 

MRNA's Revenue Growth by Quarter and Year

Moderna Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRNA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 145.00
1st Quarter March 389.00
FY 534.00

MRNAs Annual Revenue
Moderna Inc 's Revenue in the fiscal year 2025 $ 1,944.00 millions
Moderna Inc 's Revenue in the fiscal year 2024 $ 3,236.00 millions
Moderna Inc 's Revenue in the fiscal year 2023 $ 6,848.00 millions
Moderna Inc 's Revenue in the fiscal year 2022 $ 19,263.00 millions
Moderna Inc 's Revenue in the fiscal year 2021 $ 18,471.00 millions




MRNA Revenue second quarter 2026 Y/Y Growth Comment
Moderna Inc reported Revenue growth of 2.11% year on year in the second quarter 2026, to $ 145.00 millions, this is lower than Moderna Inc 's recent average Revenue surge of 16060.64%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 39 other companies have achieved higher Revenue growth. While Moderna Inc ' s Revenue increase of 2.11% ranks overall at the positon no. 2526 in the second quarter 2026.


MRNA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -29.81 % -65.64 % -44.71 %
3rd Quarter September - -45.44 % 1.69 % -45.57 %
2nd Quarter June 2.11 % -41.08 % -29.94 % -92.76 %
1st Quarter March 260.19 % -35.33 % -91.03 % -69.3 %
FY   - -39.93 % -52.75 % -

Financial Statements
Moderna Inc 's second quarter 2026 Revenue $ 145.00 millions MRNA's Income Statement
Moderna Inc 's second quarter 2025 Revenue $ 142.00 millions Quarterly MRNA's Income Statement


MRNA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -33.27 % -48.12 % 53.52 %
3rd Quarter September - 615.49 % 672.61 % 432.27 %
2nd Quarter June -62.72 % 31.48 % 44.31 % -81.53 %
1st Quarter March -42.63 % -88.82 % -94.06 % -63.38 %
FY (Year on Year)   - -39.93 % -52.75 % -


Back to MRNA Growth rate Comparisons >> Back to MRNA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #40
Healthcare Sector #358
Overall #2526

Revenue Y/Y Growth Statistics
High Average Low
309527.45 % 16060.64 % -100 %
(Sep 30 2020)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #40
Healthcare Sector #358
Overall #2526
Revenue Y/Y Growth Statistics
High Average Low
309527.45 % 16060.64 % -100 %
(Sep 30 2020)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Moderna Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
46392.79 % 1668.88 % -100 %
(Dec 31 2018)  


MRNA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Moderna Inc disclosed fall in Revenue from the first quarter by -62.72% to $ 145.00 millions, from $ 389.00 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Moderna Inc 's Revenue growth quarter on quarter, overall rank is 3651.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #61
Healthcare Sector #539
Overall #3651
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #61
Healthcare Sector #539
Overall #3651
Revenue Q/Q Growth Statistics
High Average Low
46392.79 % 1668.88 % -100 %
(Dec 31 2018)  


MRNA's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Moderna Inc disclosed fall in Revenue from the first quarter by -62.72% to $ 145.00 millions, from $ 389.00 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Moderna Inc 's Revenue growth quarter on quarter, overall rank is 3651.


Moderna Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2,228.00 $ 2,225.00 $ 1,944.00 $ 2,232.00 $ 3,078.00
Y / Y Revenue Growth (TTM) -27.62 % -29.97 % -39.93 % -56.07 % -39.05 %
Year on Year Revenue Growth Overall Ranking # 3402 # 2527 # 1158 # 3267 # 3186
Seqeuential Revenue Change (TTM) 0.13 % 14.45 % -12.9 % -27.49 % -3.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 2643 # 2026 # 2631 # 2138 # 2250


Cumulative Revenue growth Comment
Moderna Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Moderna Inc 's annual Revenue decline would be -27.62% year on year to $2,228 millions.

In the Healthcare sector 465 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2527 to 3402.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 466
Overall # 3402

Revenue TTM Y/Y Growth Statistics
High Average Low
532643.15 %
 42017.2 %
-65.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 375
S&P 500 # 2643
Cumulative Revenue growth Comment
Moderna Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Moderna Inc 's annual Revenue drop would be -27.62% year on year to $2,228 millions.

In the Healthcare sector 465 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2527 to 3402.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 40
Healthcare Sector # 466
Overall # 3402

Revenue TTM Y/Y Growth Statistics
High Average Low
532643.15 %
42017.2 %
-65.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 40
Sector # 375
S&P 500 # 2643




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRNA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Heron Therapeutics Inc 3.64%$ 3.640 millions
Prime Medicine Inc 3.50%$ 3.498 millions
Inogen Inc 3.04%$ 3.042 millions
Pacific Health Care Organization Inc2.79%$ 2.786 millions
Quidelortho Corp2.77%$ 2.769 millions
C4 Therapeutics Inc 2.75%$ 2.754 millions
Surgery Partners Inc 2.75%$ 2.748 millions
Lantheus Holdings Inc 2.69%$ 2.690 millions
Healthcare Services Group Inc 2.69%$ 2.686 millions
Adma Biologics Inc 2.61%$ 2.613 millions
Pfizer Inc2.60%$ 2.600 millions
Infusystem Holdings Inc2.59%$ 2.586 millions
Outset Medical Inc 2.49%$ 2.488 millions
3m Company2.46%$ 2.459 millions
Strata Critical Medical Inc 2.41%$ 2.408 millions
Nature s Sunshine Products inc 2.35%$ 2.350 millions
Solventum Corporation2.22%$ 2.221 millions
Adc Therapeutics Sa2.17%$ 2.171 millions
Moderna Inc 2.11%$ 2.113 millions
Co diagnostics Inc 1.98%$ 1.977 millions
Rxsight Inc 1.66%$ 1.660 millions
Bioage Labs Inc 1.62%$ 1.617 millions
Icon Plc1.20%$ 1.197 millions
Bio techne Corp1.06%$ 1.063 millions


About Moderna Inc Revenue Growth Rates (MRNA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Moderna Inc (CIK 1682852).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001682852-26-000150
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Moderna Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.